Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target s… Read more
Acumen Pharmaceuticals Inc (ABOS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.327x
Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has a cash flow conversion efficiency ratio of -0.327x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.49 Million) by net assets ($93.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acumen Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Acumen Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Acumen Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Datalogic S.p.A
OTCGREY:DLGCF
|
-0.028x |
|
Hyundai Pharm
KO:004310
|
-0.038x |
|
LH Financial Group Public Company Limited
BK:LHFG
|
0.089x |
|
Zimplats Holdings Limited
PINK:ZMPLF
|
0.089x |
|
JAPFA LTD
F:1O4
|
N/A |
|
GKW Limited
NSE:GKWLIMITED
|
-0.001x |
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
0.005x |
|
Taaleri Oyj
HE:TAALA
|
0.010x |
Annual Cash Flow Conversion Efficiency for Acumen Pharmaceuticals Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Acumen Pharmaceuticals Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $181.82 Million | $-86.22 Million | -0.474x | -193.97% |
| 2023-12-31 | $266.97 Million | $-43.06 Million | -0.161x | +13.38% |
| 2022-12-31 | $188.78 Million | $-35.15 Million | -0.186x | -133.47% |
| 2021-12-31 | $225.18 Million | $-17.96 Million | -0.080x | -119.90% |
| 2020-12-31 | $-18.59 Million | $-7.45 Million | 0.401x | -32.88% |
| 2019-12-31 | $-11.42 Million | $-6.82 Million | 0.597x | -- |